Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 27, Number 6—June 2021
Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
|Average incidence of visits per 100 children||78||59||46||NA|
*Values are rounded to the nearest whole numbers. PCV7 was approved for use in the United States in 2000; PCV13 was approved for use in the United States in 2010. NA, not applicable; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV. †Visits expected if PCVs had not been introduced. ‡Calculated by subtracting estimated visits from expected visits.